Market overview
Adenomyosis
is defined as a medical condition in which the inner lining of the uterus (also
known as the endometrium) breaks through the muscle wall of the uterus (the
myometrium). The treatment of this medical problem is called adenomyosis
treatment. A new report on the global adenomyosis treatment market, published
by Market Research Future (MRFR), states that global adenomyosis treatment
market size can visualize progress at 6.20% CAGR during the forecast period (2023-2032).
The
biggest driver for the global adenomyosis treatment market growth is the global
prevalence of adenomyosis. The increasing awareness about adenomyosis as well as
its treatment is boosting the global adenomyosis
treatment market insight by creating the
demand, supply, and sales for new drugs and therapies, along with advanced
medical technology-focused towards the adenomyosis. Hence, new opportunities
are arising for market growth. During the forecast period, increased funding
for research & development (R&D) to develop more advanced products
(medical devices) is expected to reflect favorably on the market. However, the
market in developing countries can face hurdles as many people are not aware of
this medical problem.
Key Players
Global
adenomyosis
treatment market players are Bayer AG
(Germany), Ferring B.V. (Switzerland), Johnson & Johnson Consumer Inc.
(USA), Merck KGaA (Germany), Novartis (Switzerland), Pfizer Inc. (USA) and
Speciality European Pharma (UK).
Market Segmentation
The
global adenomyosis treatment market segmentation encompasses diagnosis, type,
and treatment. MRFR’s take on the market marks various facets of the market
in-depth.
The
diagnosis-based segmentation of this market covers endometrial biopsy, magnetic
resonance imaging (MRI), ultrasound, and others. The ultrasound segment has
been sub-segmented into transabdominal ultrasound and endovaginal ultrasound
which is also known as transvaginal ultrasound.
By
type, the market includes adenomyoma, diffuse, focal, and others.
By
treatment, the market covers anti-inflammatory drugs, hormone medications, and
hysterectomy. The anti-inflammatory drugs segment has been sub-segmented into Advil,
ibuprofen, Motrin ibuprofen (Motrin IB), and others. The hormone medications
segment has been sub-segmented into aromatase inhibitors and
Gonadotropin-releasing hormone (GnRH) agonists. The hysterectomy segment
radical hysterectomy, supracervical hysterectomy (also known as a subtotal
hysterectomy), and total hysterectomy.
Regional Segmentation
A
geographical outlining of the global adenomyosis treatment market covers the
Americas (North America & South America), Asia Pacific, Europe, and the
Middle East & Africa (MEA).
The
Americas is the biggest regional market as North America alone has the
potential of becoming a powerful regional market. Due to the advanced medical
facilities being available in the USA North America is a larger regional market
segment compared to South America. North America is the largest regional market
segment due to the rapid adoption of new drugs and therapies. Continuous
innovation on the technological front and heavy use of technology in the medical
sector boost market in this region. USA and Canada are generating the maximum
revenue in this region.
Europe
is the second-largest regional market as many important market players are
based in Europe. Due to the reasons the same as in The Americas, Western Europe
is a bigger market compared to Eastern Europe. The major market share comes
from France, Germany, Spain, Italy, and the UK.
The
Asia Pacific region is an important regional market due to improving medical
sector and stable technological progress. In this report, this regional market
has been segmented into Asia and the Pacific. In Asia, the key country-specific
markets are China, India, Japan, and South Korea. An observation of the
remaining countries in Asia and the Pacific region featured in this report
calculates the additional market revenue from some other countries.
In
the MEA region, the market has been slow due to limited availability of
advanced medical facilities. Countries focused in the report include Egypt, Saudi
Arabia, and the UAE.
About
US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact
us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street,5Th Floor, New York,
New
York 10013
United
States of America
